Literature DB >> 22308055

Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?

Philipp Thiel1, Markus Kaiser, Christian Ottmann.   

Abstract

The modulation of protein-protein interactions (PPIs) has been recognized as one of the most challenging tasks in drug discovery. While their systematic development has long been considered as intractable, this view has changed over the last years, with the first drug candidates undergoing clinical studies. To date, the vast majority of PPI modulators are interaction inhibitors. However, in many biological contexts a prolonged lifespan of a PPI might be desirable, calling for the complementary approach of PPI stabilization. In fact, nature offers impressive examples of this concept and some PPI-stabilizing natural products have already found application as important drugs. Moreover, directed small-molecule stabilization has recently been demonstrated. Therefore, it is time to take a closer look at the constructive side of modulating PPIs.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Mesh:

Substances:

Year:  2012        PMID: 22308055     DOI: 10.1002/anie.201107616

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  49 in total

Review 1.  Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes.

Authors:  Stuart L Schreiber; Joanne D Kotz; Min Li; Jeffrey Aubé; Christopher P Austin; John C Reed; Hugh Rosen; E Lucile White; Larry A Sklar; Craig W Lindsley; Benjamin R Alexander; Joshua A Bittker; Paul A Clemons; Andrea de Souza; Michael A Foley; Michelle Palmer; Alykhan F Shamji; Mathias J Wawer; Owen McManus; Meng Wu; Beiyan Zou; Haibo Yu; Jennifer E Golden; Frank J Schoenen; Anton Simeonov; Ajit Jadhav; Michael R Jackson; Anthony B Pinkerton; Thomas D Y Chung; Patrick R Griffin; Benjamin F Cravatt; Peter S Hodder; William R Roush; Edward Roberts; Dong-Hoon Chung; Colleen B Jonsson; James W Noah; William E Severson; Subramaniam Ananthan; Bruce Edwards; Tudor I Oprea; P Jeffrey Conn; Corey R Hopkins; Michael R Wood; Shaun R Stauffer; Kyle A Emmitte
Journal:  Cell       Date:  2015-06-04       Impact factor: 41.582

Review 2.  The re-emergence of natural products for drug discovery in the genomics era.

Authors:  Alan L Harvey; RuAngelie Edrada-Ebel; Ronald J Quinn
Journal:  Nat Rev Drug Discov       Date:  2015-01-23       Impact factor: 84.694

Review 3.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

4.  Exploring key orientations at protein-protein interfaces with small molecule probes.

Authors:  Eunhwa Ko; Arjun Raghuraman; Lisa M Perez; Thomas R Ioerger; Kevin Burgess
Journal:  J Am Chem Soc       Date:  2012-12-27       Impact factor: 15.419

5.  Identification of the β-lactamase inhibitor protein-II (BLIP-II) interface residues essential for binding affinity and specificity for class A β-lactamases.

Authors:  Nicholas G Brown; Dar-Chone Chow; Kevin E Ruprecht; Timothy Palzkill
Journal:  J Biol Chem       Date:  2013-04-27       Impact factor: 5.157

Review 6.  Long-term delivery of protein therapeutics.

Authors:  Ravi Vaishya; Varun Khurana; Sulabh Patel; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2014-09-24       Impact factor: 6.648

7.  Structural basis for the recognition-evasion arms race between Tomato mosaic virus and the resistance gene Tm-1.

Authors:  Kazuhiro Ishibashi; Yuichiro Kezuka; Chihoko Kobayashi; Masahiko Kato; Tsuyoshi Inoue; Takamasa Nonaka; Masayuki Ishikawa; Hiroyoshi Matsumura; Etsuko Katoh
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

Review 8.  Taspase1: a 'misunderstood' protease with translational cancer relevance.

Authors:  D Wünsch; A Hahlbrock; S Jung; T Schirmeister; J van den Boom; O Schilling; S K Knauer; R H Stauber
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

9.  Therapeutic potential of small molecules and engineered proteins.

Authors:  Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014

10.  Sekikaic acid and lobaric acid target a dynamic interface of the coactivator CBP/p300.

Authors:  Chinmay Y Majmudar; Jonas W Højfeldt; Carl J Arevang; William C Pomerantz; Jessica K Gagnon; Pamela J Schultz; Laura C Cesa; Conor H Doss; Steven P Rowe; Victor Vásquez; Giselle Tamayo-Castillo; Tomasz Cierpicki; Charles L Brooks; David H Sherman; Anna K Mapp
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-08       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.